CoreRx Teams with leon-nanodrugs to Offer Nano-based MicroJet Reactor (MJR®) Drug Formulations

CoreRx and leon-nanodrugs announced their cooperation for the establishment of a dedicated laboratory at the CoreRx Myerlake facility that will house leon-nanodrugs’ proprietary nanotechnology platform – MicroJet Reactor (MJR). The lab will focus on technical feasibility work through final formulation for oral, semi-solid, and liquid preparations utilizing the novel MJR nanotechnology.
According to the news:

leon-nanodrugs focuses on developing innovative drug formulations enabled by its proprietary nanotechnology platform – MicroJet Reactor (MJR).  leon works with its Pharma customers through contract development agreements, as well as co-development partnerships.  leon has also initiated work on its own internal development projects, concentrating on nanotechnology-based reformulations that offer enhanced clinical and safety benefits.

Dr. Theron E. Odlaug, CEO of leon-nanodrugs GmbH and the US subsidiary commented:

The vision of leon-nanodrugs is to be recognized as a global leader in nanotechnology formulated pharmaceuticals through contract services and co-development partnerships.  Through the unique attributes of our MicroJet Reactor Technology, our goal is to generate added value to both established molecules and novel NCEs.  The partnership with CoreRx represents a key step for leon as we can offer our Pharma partners a second state of the art facility for developing enhanced nanotechnology-enabled formulations for new and existing compounds.

Click here to view the full press release.